Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2016118654 - COMPOSITIONS ET PROCÉDÉS POUR IMMUNOTHÉRAPIE DE CANCER

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

What is claimed is:

1. A composition comprising β-Ι,ό-glucan linked to an antibody, wherein the antibody is directed to a surface feature of a T regulatory cell.

2. The composition of claim 1, wherein the antibody is a monoclonal antibody.

3. The composition of claim 1, wherein the antibody is a human antibody.

4. The composition of claim 1, wherein the antibody is a humanized antibody.

5. The composition of claim 1, wherein the antibody is an antibody fragment.

6. The composition of claim 1, wherein the β-Ι,ό-glucan is derived from a fungal glucan.

7. The composition of claim 1, wherein the β-Ι,ό-glucan is derived from pustulan.

8. The composition of claim 1, wherein the β-Ι,ό-glucan is derived from a fungal glucan via one or more processing steps that include hydrolysis and/or enzymatic digestion.

9. The composition of claim 1, wherein the β-Ι,ό-glucan is chemically synthesized.

10. The composition of claim 1, wherein the β-Ι,ό-glucan is genetically engineered.

11. The composition of claim 1, wherein the β-Ι,ό-glucan is synthesized in a bacteria, yeast, or mammalian cell.

12. The composition of claim 1, wherein the β-Ι,ό-glucan is soluble.

13. The composition of claim 1, wherein the β-Ι,ό-glucan comprises a structural modification selected from the group consisting of O-acetylation, methylation, alkylation, esterification, alkoylation, sulfation, phosphorylation, lipid conjugation and combinations thereof.

14. The composition of claim 1, wherein the β-Ι,ό-glucan has a molecular weight less than 100 kDa.

15. The composition of claim 1, wherein the β-Ι,ό-glucan contains fewer than 85 glucose monosaccharide units.

16. The composition of claim 1, wherein the β-Ι,ό-glucan contains 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, or 65 glucose monosaccharide units.

17. The composition of claim 1, wherein the β-Ι,ό-glucan contains 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, or 44 glucose monosaccharide units.

18. The composition of claim 1, wherein the β-Ι,ό-glucan contains 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, or 23 glucose monosaccharide units.

19. The composition of claim 1, wherein the β-Ι,ό-glucan contains 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, or 3 glucose monosaccharide units.

20. The composition of claim 1, wherein at least 90% of the dry weight of glucan contained in the composition is β-Ι,ό-glucan.

21. The composition of claim 1, wherein less than 10% of the dry weight of glucan contained in the composition is β-Ι-3-glucan.

22. The composition of claim 1, wherein the composition is substantially free of β-1-3-glucan.

23. The composition of claim 1, wherein the β-Ι,ό-glucan is directly linked to the antibody.

24. The composition of claim 1, wherein the β-Ι,ό-glucan is linked to the antibody via a linker molecule.

25. The composition of claim 1, wherein the β-Ι,ό-glucan is linked to the antibody via amide, aldehyde, urethane, imine or disulfide formation between the respective molecules, or between a linker molecule and the respective molecules.

26. A method of treating cancer, said method comprising administering to a subject in need thereof a composition comprising β-Ι,ό-glucan linked to an antibody, wherein the antibody is directed to a surface feature of a T regulatory cell.

27. The method of claim 26, wherein the antibody is a monoclonal antibody.

28. The method of claim 26, wherein the antibody is a human antibody.

29. The method of claim 26, wherein the antibody is a humanized antibody.

30. The method of claim 26, wherein the antibody is an antibody fragment.

31. The method of claim 26, wherein the β-Ι,ό-glucan is derived from a fungal glucan.

32. The method of claim 26, wherein the β-Ι,ό-glucan is derived from pustulan.

33. The method of claim 26, wherein the β-Ι,ό-glucan is derived from a fungal glucan via one or more processing steps that include hydrolysis and/or enzymatic digestion.

34. The method of claim 26, wherein the β-Ι,ό-glucan is chemically synthesized.

35. The method of claim 26, wherein the β-Ι,ό-glucan is genetically engineered.

36. The method of claim 26, wherein the β-Ι,ό-glucan is synthesized in a bacteria, yeast, or mammalian cell.

37. The method of claim 26, wherein the β-Ι,ό-glucan is soluble.

38. The method of claim 26, wherein the β-Ι,ό-glucan comprises a structural modification selected from the group consisting of O-acetylation, methylation, alkylation, esterification, alkoylation, sulfation, phosphorylation, lipid conjugation and combinations thereof.

39. The method of claim 26, wherein the β-Ι,ό-glucan has a molecular weight less than 100 kDa.

40. The method of claim 26, wherein the β-Ι,ό-glucan contains fewer than 85 glucose monosaccharide units.

41. The method of claim 26, wherein the β-Ι,ό-glucan contains 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, or 65 glucose monosaccharide units.

42. The method of claim 26, wherein the β-Ι,ό-glucan contains 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, or 44 glucose monosaccharide units.

43. The method of claim 26, wherein the β-Ι,ό-glucan contains 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, or 23 glucose monosaccharide units.

44. The method of claim 26, wherein the β-Ι,ό-glucan contains 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, or 3 glucose monosaccharide units.

45. The method of claim 26, wherein at least 90% of the dry weight of glucan contained in the composition is β-Ι,ό-glucan.

46. The method of claim 26, wherein less than 10% of the dry weight of glucan contained in the composition is β-Ι-3-glucan.

47. The method of claim 26, wherein the composition is substantially free of β-Ι-3-glucan.

48. The method of claim 26, wherein the β-Ι,ό-glucan is directly linked to antibody.

49. The method of claim 26, wherein the β-Ι,ό-glucan is linked to the antibody via a linker molecule.

50. The method of claim 26, wherein the β-Ι,ό-glucan is linked to the targeting moiety via amide, urethane, imine or disulfide formation between the respective molecules, or between a linker molecule and the respective molecules.

51. A method of modulating an immune response, said method comprising administering to a subject in need thereof a composition comprising β-Ι,ό-glucan linked to an antibody, wherein the antibody is directed to a surface feature of a T regulatory cell.

52. The method of claim 51, wherein the antibody is a monoclonal antibody.

53. The method of claim 51, wherein the antibody is a human antibody.

54. The method of claim 51, wherein the antibody is a humanized antibody.

55. The method of claim 51, wherein the antibody is an antibody fragment.

56. The method of claim 51, wherein the β-Ι,ό-glucan is derived from a fungal glucan.

57. The method of claim 51, wherein the β-Ι,ό-glucan is derived from pustulan.

58. The method of claim 51, wherein the β-Ι,ό-glucan is derived from a fungal glucan via one or more processing steps that include hydrolysis and/or enzymatic digestion.

59. The method of claim 51, wherein the β-Ι,ό-glucan is chemically synthesized.

60. The method of claim 51, wherein the β-Ι,ό-glucan is genetically engineered.

61. The method of claim 51, wherein the β-Ι,ό-glucan is synthesized in a bacteria, yeast, or mammalian cell.

62. The method of claim 51, wherein the β-Ι,ό-glucan is soluble.

63. The method of claim 51, wherein the β-Ι,ό-glucan comprises a structural modification selected from the group consisting of O-acetylation, methylation, alkylation, esterification, alkoylation, sulfation, phosphorylation, lipid conjugation and combinations thereof.

64. The method of claim 51, wherein the β-Ι,ό-glucan has a molecular weight less than 100 kDa.

65. The method of claim 51, wherein the β-Ι,ό-glucan contains fewer than 85 glucose monosaccharide units.

66. The method of claim 51, wherein the β-Ι,ό-glucan contains 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, or 65 glucose monosaccharide units.

67. The method of claim 51, wherein the β-Ι,ό-glucan contains 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, or 44 glucose monosaccharide units.

68. The method of claim 51, wherein the β-Ι,ό-glucan contains 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, or 23 glucose monosaccharide units.

69. The method of claim 51, wherein the β-Ι,ό-glucan contains 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, or 3 glucose monosaccharide units.

70. The method of claim 51 , wherein at least 90% of the dry weight of glucan contained in the composition is β-Ι,ό-glucan.

71. The method of claim 51, wherein less than 10% of the dry weight of glucan contained in the composition is β-Ι-3-glucan.

72. The method of claim 51, wherein the composition is substantially free of β-Ι-3-glucan.

73. The method of claim 51, wherein the β-Ι,ό-glucan is directly linked to antibody.

74. The method of claim 51, wherein the β-Ι,ό-glucan is linked to the antibody via a linker molecule.

75. The method of claim 51, wherein the β-Ι,ό-glucan is linked to the antibody via amide, urethane, imine or disulfide formation between the respective molecules, or between a linker molecule and the respective molecules.

76. A composition comprising β-Ι,ό-glucan linked to an antagonistic anti-PDl antibody.

77. A composition comprising β-Ι,ό-glucan linked to an antagonistic anti-CTLA-4 antibody.

78. A composition comprising β-Ι,ό-glucan linked to an antagonistic anti-TIM-3 antibody.

79. A composition comprising β-Ι,ό-glucan linked to an antagonistic anti-LAG-3 antibody.

80. A composition comprising β-Ι,ό-glucan linked to an antagonistic anti-ICOS antibody.

81. A composition comprising β-Ι,ό-glucan linked to an antagonistic anti-TIGIT antibody.

82. A composition comprising β-Ι,ό-glucan linked to an agonistic anti-GITR antibody.

83. A composition comprising β-Ι,ό-glucan linked to an agonistic anti-OX-40 antibody.

84. A composition comprising β-Ι,ό-glucan linked to an agonistic anti-CD40 antibody.

85. A composition comprising β-Ι,ό-glucan linked to pembrolizumab.

86. A composition comprising β-Ι,ό-glucan linked to nivolumab.

87. A composition comprising β-Ι,ό-glucan linked to ipilimumab.

88. A composition comprising β-Ι,ό-glucan linked to MK-4166.